Hydrogen peroxide signalling in Candida albicans. (360G-Wellcome-089930_B_09_Z)

£93,292

A major fungicidal mechanism employed by the immune system is the generation of ROS. However, the fungal pathogen Candida albicans is relatively resistant to ROS and can evade killing by macrophages. Indeed, responses to ROS are tightly linked with C. albicans virulence, yet little is known regarding the signalling mechanisms underlying such responses. Significantly, our pilot experiments revealed that the thioredoxin protein, Trx1, has vital signalling functions in C. albicans and regulates two major responses to ROS; activation of the Hog1 SAPK, and H2O2-induced filamentation. Furthermore, we find that trx1Δ cells display attenuated virulence in a mouse model of systemic candidiasis. No previous studies have identified mechanisms underlying ROS-induced filamentation, or have implicated thioredoxin in regulating a fungal SAPK pathway. Moreover, the virulence defect exhibited by trx1 cells highlights the potential importance of such processes in promoting C. albicans survival in the host. This project, which builds on a strong platform of data and combines the strengths of Newcastle and Aberdeen in C. albicans stress responses and virulence, has the following goals: to delineate the mechanisms of Trx1 regulation of the Hog1 SAPK and H2O2-induced morphogenesis and to explore which aspects of Trx1 function are important for virulence.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 93292
Applicant Surname Erwig
Approval Committee Immunology and Infectious Disease Funding Committee
Award Date 2009-10-01T00:00:00+00:00
Financial Year 2009/10
Grant Programme: Title Project Grant
Internal ID 089930/B/09/Z
Lead Applicant Dr Lars Erwig
Partnership Value 93292
Planned Dates: End Date 2013-02-28T00:00:00+00:00
Planned Dates: Start Date 2010-03-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Scotland